Evidence map›Paper›PMID 39205294›Full record

ArticleViruses2024

QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro.

Nicolas M S Galvez, Maegan L Sheehan, Allen Z Lin, Yi Cao, Evan C Lam, Abigail M Jackson, Alejandro B Balazs

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nicolas M S GalvezRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0003-2046-7882
Maegan L SheehanRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA 02139, USA.
Allen Z LinRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0001-5105-308X
Yi CaoRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA 02139, USA.
Evan C LamRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-5556-2559
Abigail M JacksonRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0001-9749-9431
Alejandro B BalazsRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-1767-3944

Funding

Polyclonal Bi-Specific Vectored ImmunoTherapy to Functionally Cure HIV InfectionDP1DA060607 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Alejandro Benjamin Balazs · 2024 to 2026
$3.2M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Eliminating the Immunogenicity of AAV Vectored HIV Antibody DeliveryR01AI174276 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Alejandro Benjamin Balazs · 2024 to 2026
$2.5M
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIVR01AI174875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2023 to 2024
$1.6M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS AI174276NIAID NIH HHS AI174875NIAID NIH HHS R01 AI174276NIAID NIH HHS R01 AI174875NIDA NIH HHS 1DP1DA060607NIDA NIH HHS DP1 DA060607NIDA NIH HHS DP2 DA040254NIDA NIH HHS DP2DA040254
6 · The paper itself

Abstract

Quantifying viral growth rates is key to understanding evolutionary dynamics and the potential for mutants to escape antiviral drugs. Defining evolutionary escape paths and their impact on viral fitness allows for the development of drugs that are resistant to escape. In the case of HIV, combination antiretroviral therapy can successfully prevent or treat infection, but it relies on strict adherence to prevent escape. Here, we present a method termed QuickFit that enables the quantification of viral fitness by employing large numbers of parallel viral cultures to measure growth rates accurately. QuickFit consistently recapitulated HIV growth measurements obtained by traditional approaches, but with significantly higher throughput and lower rates of error. This method represents a promising tool for rapid and consistent evaluation of viral fitness.

Indexed as

Virus ReplicationCell LineGenetic FitnessHigh-Throughput Screening AssaysHIVHIV-1HIV InfectionsHumansReal-Time Polymerase Chain Reactionhigh-throughputHIVp24 ELISAQuickFitRT-qPCRviral fitnessviral growth

Identifiers

PMID39205294
PMCPMC11360610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.